(Reuters) — A unit of medical device maker Medtronic PLC must pay $106.5 million to rival Colibri Heart Valve LLC for patent infringement, a federal jury in Santa Ana, California, said on Wednesday.
The jury found after a seven-day trial that Medtronic CoreValve LLC’s Evolut devices infringe on a Colibri patent for replacing heart valves in heart disease patients, representatives for the companies confirmed Thursday.
A spokesperson for Medtronic said the Minneapolis-headquartered company disagrees with the ruling and will appeal. A lawyer for Colibri said it is “honored” by the jury’s “recognition of Colibri’s valuable contribution to the treatment of heart disease.”;
Colorado-based Colibri sued Medtronic in 2020. It alleged that doctors use Medtronic’s devices in a way that infringes on Colibri’s patents, which cover a method for controlling the deployment of self-expanding artificial heart valves.
The patent relates to Colibri’s own heart valve implant system.